| Date | Title | | | 12/23/02 | Neurocrine Biosciences Reports IL-4 Fusion Toxin (NBI-3001) Results
For Glioblastoma and Preliminary Results in Peripheral Cancers| SAN DIEGO, Dec. 23 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from its
second trial with IL-4 Fusion Toxin (NBI-3001) for the treatment of
glioblastoma multiforme (GBM) malignant brain tumors. An earlier study had
shown NBI-3001 to be safe with demonstrated anti-tumor effects in the majority
of patients receiving NBI-3001. The recently completed study was designed to
explore an improved delivery regimen and to determine a safe and optima... |
|  | | 12/19/02 | Neurocrine, Pfizer Announce Webcast and Conference Call on
Worldwide Agreement to Develop, Promote Insomnia Treatment| SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Pfizer Inc. (NYSE: PFE) today
announced that the two companies will host a Conference Call and Webcast to
report on their global agreement for the exclusive worldwide development and
commercialization of indiplon, Neurocrine's Phase III compound for the
treatment of insomnia. Gary Lyons, President and CEO of Neurocrine and Hank
McKinnell, Ph.D., Pfizer's Chairman of the Board and CEO will discuss ... |
| | | 12/19/02 | Neurocrine, Pfizer Announce Worldwide Agreement To Develop,
Promote Insomnia Treatment| Indiplon in Phase III Development
for Multiple Aspects of Insomnia SAN DIEGO, and NEW YORK, Dec. 19 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Pfizer Inc today announced a
global agreement for the exclusive worldwide development and commercialization
of indiplon, Neurocrine's Phase III compound for the treatment of insomnia.
In addition, Neurocrine will have the opportunity to detail Pfizer's
antidepressant Zoloft(R) (sertraline HC... |
| | | 11/18/02 | Neurocrine Biosciences Announces the Appointment Of
W. Thomas Mitchell to Its Board of Directors| SAN DIEGO, Nov. 18 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has
elected W. Thomas Mitchell to its Board of Directors effective immediately.
Mr. Mitchell is the current Chairman and former Chief Executive Officer of
Genencor International (Nasdaq: GCOR). "We are fortunate to have a person of Tom Mitchell's caliber join our
Board of Directors. Tom brings to the board, experience not only in the
industry, but more critically in the da... |
| | | 11/14/02 | Neurocrine Biosciences Announces Webcast and Conference Call
Company to Present Positive Results From First Phase III Clinical Trial
With indiplon-IR in 593 Subjects With Transient Insomnia| SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will host a Conference Call and Webcast to report on the positive Phase III
clinical trial results with indiplon-IR for Transient Insomnia. The
Conference Call and Webcast will be held today, Thursday, November 14, 2002 at
9:00AM Eastern Standard Time (EST)/6:00AM Pacific Standard Time (PST).
Participants may access the live Conference Call by dialing 1-800-547-8913
(... |
| | | 11/14/02 | Neurocrine Biosciences Reports Positive Results From First
Phase III Clinical Trial With indiplon-IR in 593 Subjects With Transient
Insomnia
Indiplon-IR Demonstrates Statistically Significant Improvement in Mul| SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive results
from the Company's first Phase III clinical trial with indiplon-IR capsules,
achieving both primary and secondary endpoints of sleep initiation. The study
enrolled 593 subjects with Transient Insomnia. Results demonstrated that
indiplon-IR was safe, well tolerated, and effective in these subjects with
Transient Insomnia, achieving rapid sleep induction without next day ... |
| | | 11/13/02 | Neurocrine Biosciences to Present at Credit Suisse First Boston
Health Care Conference| SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the Credit Suisse First Boston Health Care Conference in
Phoenix, Arizona at the Arizona Biltmore on Thursday, November 14, 2002 at
2:00PM Eastern Standard Time; 12:00PM Mountain Time; and 11:00AM Pacific
Standard Time. The presentation will be simultaneously webcast and can be
accessed on the Company's website only at the time specified above at
... |
| | | 11/01/02 | Neurocrine Biosciences to Present at CIBC World Markets Health Care Conference|
SAN DIEGO, Nov. 1 --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the CIBC World Markets Health Care Conference in New
York at the Plaza Hotel on Monday, November 4, 2002 at 9:00AM Eastern Standard
Time (6:00AM Pacific Standard Time). The presentation will be simultaneously
webcast and can be accessed on the Company's website at
http://www.neurocrine.com or through a link provided by CIBC World Markets at
http://e... |
| | | 10/30/02 | Neurocrine Biosciences Reports Third Quarter 2002 Results|
SAN DIEGO, Oct. 30 --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial
results for the third quarter ended September 30, 2002. For the three months
ended September 30, 2002, the Company reported net loss of $20.2 million or
$0.66 per share compared to net income of $2.5 million, or $0.09 per share
diluted for the same period last year. For the nine months ended
September 30, 2002 the Company had a net loss of $55.7 million, or $1.83 per
share com... |
| | | 10/28/02 | Neurocrine Biosciences Announces Webcast and Conference Call to Present|
Third Quarter 2002 Results and Company Update
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report third quarter financial results on Wednesday, October 30, 2002.
Neurocrine will also host a Conference Call and Webcast to discuss its
financial results and provide a company update on Thursday, October 31, 2002
at 11:00AM Eastern Standard Time (EST) /8:00AM Pacific Standard Time (PST).
Participants m... |
| | | 10/25/02 | Neurocrine Biosciences to Present at Salomon Smith Barney Citigroup 2002 Global Health Care Conference|
SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the Salomon Smith Barney Citigroup 2002 Global Health
Care Conference in New York at the Plaza Hotel on Monday, October 28, 2002 at
10:15AM Eastern Standard Time (7:15AM Pacific Standard Time) The presentation
will be simultaneously webcast and can be accessed at
http://www.veracast.com/ssb/2002/healthcare/41105362.cfm or through a link
provi... |
| | | 10/25/02 | Neurocrine Biosciences to Present at Salomon Smith Barney Citigroup 2002 Global Health Care Conference|
SAN DIEGO, Oct. 25 --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the Salomon Smith Barney Citigroup 2002 Global Health
Care Conference in New York at the Plaza Hotel on Monday, October 28, 2002 at
10:15AM Eastern Standard Time (7:15AM Pacific Standard Time) The presentation
will be simultaneously webcast and can be accessed at
http://www.veracast.com/ssb/2002/healthcare/41105362.cfm or through a link
provided via ... |
| | | 10/14/02 | Neurocrine Biosciences and Taisho Pharmaceutical Announce Agreement Restructuring| SAN DIEGO, Oct. 14 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today the restructuring
of its exclusive agreement with Taisho Pharmaceutical Co., Ltd. The original
agreement signed in January 2000, provided Taisho an option to obtain European
and Asian commercialization rights for Neurocrine's altered peptide ligand
(APL) (NBI-6024) for diabetes mellitus with Neurocrine retaining all rights in
the rest of the world including North America. In July 20... |
| | | 10/07/02 | Neurocrine Biosciences to Present at UBS Warburg|
Global Life Sciences Conference
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the UBS Warburg Global Life Sciences Conference in New
York at the Plaza Hotel on Tuesday, October 8, 2002 at 2:30PM Eastern Daylight
Time (11:30AM Pacific Daylight Time). The presentation may be accessed via an
audio webcast only at www.ubswarburg.com . Click on the UBS Warburg
conference link in the lo... |
| | | 09/20/02 | Neurocrine Biosciences to Present at Banc of America Securities 32nd Annual Investment Conference| SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the Banc of America Securities 32nd Annual Investment
Conference held in San Francisco on Monday, September 23, 2002 at 11:15AM
Pacific Daylight Time (2:15PM Eastern Daylight Time). The presentation will
be simultaneously webcast and can be viewed through a link provided via the
Company's website at http://www.neurocrine.com Gary Lyons, Pres... |
| | | 09/16/02 | Neurocrine Biosciences to Present at Bear Stearns 15th Annual Healthcare Conference| SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at Bear Stearns 15th Annual Healthcare Conference held in
New York on Tuesday, September 17, 2002 at 11:30AM Eastern Daylight Time
(8:30AM Pacific Daylight Time). The presentation will be simultaneously
webcast and can be viewed through a link provided via the Company's website at
http://www.neurocrine.com Gary Lyons, President and CEO of Neuro... |
| | | 08/13/02 | Neurocrine Biosciences Awarded $1.5M SBIR Grant From NIH to Support GPCR Library Design, Synthesis and Evaluation| SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
has received a Phase-II Small Business Innovation Research (SBIR) grant from
the National Institutes of Health (NIH). This new grant totals more than
$1.5M over a two year period to support the further development of a novel
screening library of compounds targeted towards G-protein coupled receptors
(GPCRs). Results obtained by Neurocrine scientists during Phase-I... |
| | | 07/30/02 | Neurocrine Biosciences Reports Second Quarter 2002 Results| SAN DIEGO, July 30 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial
results for the second quarter ended June 30, 2002. The Company reported a
net loss of $19.8 million or $0.65 per share and $35.5 million or $1.17 per
share for the three and six months ended June 30, 2002, respectively. These
results compare with $13.3 million or $0.52 per share and $24.8 million or
$0.97 per share for the respective periods in 2001. Revenues for t... |
| | | 07/29/02 | Neurocrine Biosciences Announces Webcast and Conference Call To Present Second Quarter 2002 Results and Company Update| SAN DIEGO, July 29 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report second quarter financial results on Tuesday, July 30, 2002.
Neurocrine will also host a Conference Call and Webcast to discuss its
financial results and provide a company update on Wednesday, July 31, 2002 at
9:00AM Eastern Daylight Time (EDT)/6:00AM Pacific Daylight Time (PDT).
Participants may access the live Conference Call by dialing 1-800-233-2795
(US)... |
| | | 07/29/02 | Neurocrine Biosciences Announces Webcast and Conference Call To Present Second Quarter 2002 Results and Company Update| SAN DIEGO, July 29 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report second quarter financial results on Tuesday, July 30, 2002.
Neurocrine will also host a Conference Call and Webcast to discuss its
financial results and provide a company update on Wednesday, July 31, 2002 at
9:00AM Eastern Daylight Time (EDT)/6:00AM Pacific Daylight Time (PDT).
Participants may access the live Conference Call by dialing 1-800-233-2795
(US)... |
| | | 06/25/02 | Neurocrine Biosciences Initiates Final Phase III Clinical Trial With Indiplon-IR (Immediate Release)| SAN DIEGO, June 25 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it is
initiating the final pivotal Phase III clinical trial with indiplon-IR
(Immediate Release). The Company is now conducting six of eight planned Phase
III clinical trials with indiplon IR and MR (Modified Release) and expects to
initiate the remaining Phase III clinical trials with indiplon-MR this year.
According to the clinical program agreed upon by the Food and Drug
Admin... |
| | | 06/24/02 | Neurocrine Biosciences Announces Positive Phase II Efficacy and Safety Results With Indiplon-MR (Modified Release Formulation)| In Elderly Patients With Primary Insomnia
SAN DIEGO, June 24 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive efficacy
and safety results with indiplon-MR tablets in a Phase II clinical trial in
79 elderly patients with Primary (Chronic) Insomnia characterized by sleep
maintenance difficulties. This study was a randomized, multi-center,
double-blind, placebo-controlled, five-period crossover, dose-response study,
in which four dose leve... |
| | | 06/24/02 | Neurocrine Biosciences Announces Webcast on Results of Phase II Clinical Trial With Indiplon-MR in Elderly Patients With Primary Insomnia| SAN DIEGO, June 24 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will host a Webcast to discuss the positive efficacy and safety results of its
Phase II clinical trial with indiplon-MR in elderly patients with Primary
(Chronic) Insomnia on Monday, June 24, 2002 at 10:00 AM Eastern Daylight Time
(EDT)/ 7:00 AM Pacific Daylight Time (PDT). Participants may access this
webcast through a link provided via the Company's website at
www.n... |
| | | 06/14/02 | Neurocrine Biosciences Reports Additional Phase I/II Safety Results With NBI-6024 in Adolescent Patients With Type 1 Diabetes| (ADA) Meeting in San Francisco June 14-18
SAN DIEGO, June 14 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today new additional
Phase I/II safety results of NBI-6024 for Type I diabetes will be presented
this week at the 62nd Annual Meeting of the American Diabetes Association
(ADA) in San Francisco. NBI-6024, which Neurocrine is developing in
collaboration with Taisho Pharmaceutical Co., Ltd., is a therapeutic vaccine
developed using Neurocrine's A... |
| | | 06/12/02 | Neurocrine Biosciences Announces Indiplon (NBI-34060) Data Presented at the Associated Professional Sleep Societies (APSS) Meeting|
Results Demonstrate No Significant Differences in the PK Profiles
For Gender nor Age
SAN DIEGO, June 12 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that data from two
Phase I pharmacokinetic (PK) clinical trials with indiplon (NBI-34060) will be
presented at the 16th Annual Meeting of Associated Professional Sleep
Societies (APSS) in Seattle, June 10-12, 2002. The elderly and female
population represe... |
| | | 06/04/02 | Neurocrine Biosciences Initiates First Efficacy and Safety Phase III Clinical Trial for Indiplon-MR (Modified Release Formulation) in Primary Insomnia|
Neurocrine Also Announces That Enrollment Has Been Completed
In a 500 Patient Long-Term Safety Phase III Study for Indiplon-IR
SAN DIEGO, June 4 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it is
initiating the first of three pivotal Phase III clinical trials with
indiplon-MR (Modified Release Formulation of NBI-34060), the Study of
Long-term Efficacy and Safety of indiplon-MR in Primary Insomnia (referred to
as the SL... |
| | | 06/04/02 | Neurocrine Biosciences Announces U.S. Issuance of Composition of Matter Patent for Its Phase III Insomnia Compound|
18 Years of Patent Exclusivity of Indiplon (NBI-34060)
Indiplon Is the New Development Name for NBI-34060
SAN DIEGO, June 4 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today the issuance of
U.S. Patent No. 6,399,621 (the '621 patent) covering the chemical composition
of its proprietary compound indiplon (NBI-34060) for the treatment of
insomnia. The '621 patent will provide Neurocrine with patent exclusivity for
in... |
| | | 06/04/02 | Neurocrine Biosciences Announces Webcast on Indiplon (NBI-34060)| Indiplon IR and MR on Track to Meet Schedule for Market Registration
SAN DIEGO, June 4 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will host a webcast to discuss the patent exclusivity of indiplon (NBI-34060)
and phase III clinical program on Tuesday, June 4, 2002 at 9:00 AM Eastern
Daylight Time (EDT)/ 6:00 AM Pacific Daylight Time (PDT). Participants may
access this webcast through a link provided via the Company's website... |
| | | 05/31/02 | Neurocrine Biosciences To Present at the First Annual Needham & Company Biotechnology Conference| SAN DIEGO, May 31 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the First Annual Needham & Company Biotechnology
Conference held in New York. The webcast will be held Tuesday, June 4, 2002 at
11:00 AM Eastern Daylight Time (EDT)/ 8:00 AM Pacific Daylight Time (PDT).
Participants may access this webcast through a link provided via the Company's
website at www.neurocrine.com or alternatively at
http://www.tws... |
| | | 05/07/02 | Neurocrine Biosciences Announces Positive Phase I Results With Its Proprietary, Orally Active GnRH Receptor Antagonist For Women's Health Disorders and Prostate Cancer|
First-in-Human Study Shows Proof of Concept With
Effective Supression of Hormone Levels
SAN DIEGO, May 7 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today the completion of
the first Phase I clinical trial with its proprietary, orally active small
molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist compound
for the treatment of women's health disorders and prostate cancer. Initial
pharmacokine... |
| | | 05/07/02 | Neurocrine Biosciences to Present at Deutsche Bank Securities 27th Annual Health Care 2002 Conference| SAN DIEGO, May 7 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the Deutsche Bank Securities 27th Annual Health Care
2002 Conference held in Baltimore today, Tuesday, May 7, 2002 at 3:30PM
Eastern Daylight Time (12:30PM Pacific Daylight Time). The presentation will
be simultaneously webcast and can be viewed through a link provided via the
Company's website at http://www.neurocrine.com Gary Lyons, President... |
| | | 05/01/02 | Neurocrine Biosciences, Inc. Announces Extension of Collaboration With Wyeth in Glutamate Transporter Research| Scientists at Neurocrine and Wyeth Discover EAAT-3 Inhibitors
SAN DIEGO, May 1 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today the extension of
its research collaboration with Wyeth (NYSE: WYE). The focus of the
collaboration is the Excitatory Amino Acid Transporter (EAAT) sub-type, EAAT-3
with applications to treat schizophrenia, Alzheimer's disease and other
nervous system disorders. Neurocrine and Wyeth scientists have been
successful in id... |
| | | 04/30/02 | Neurocrine Biosciences to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference| SAN DIEGO, April 30 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will be presenting at the CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference being held in New York on Wednesday, May 1, 2002 at
10:30AM Eastern Daylight Time (7:30AM Pacific Daylight Time). The
presentation will be simultaneously webcast and can be viewed through a link
provided via the Company's website at http://www.neurocrine.com ... |
| | | 04/29/02 | Neurocrine Biosciences Reports First Quarter 2002 Results| SAN DIEGO, April 29 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial
results for the quarter ended March 31, 2002. For the first quarter the
Company reported a net loss of $15.8 million, or $0.52 per share compared with
a net loss of $11.5 million or $0.45 per share for the same period last year. Revenues for the first quarter of 2002 were $5.0 million compared with
$3.5 million for the same period last year. The net increase in reven... |
| | | 03/19/02 | Neurocrine Biosciences Ramps Up Phase III Clinical Trials for NBI-34060 In Primary (Chronic) and Transient Insomnia|
The Company Is on Track Initiating the Most Comprehensive
Clinical Program in Insomnia
SAN DIEGO, March 19 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it is
initiating three additional pivotal Phase III clinical trials of NBI-34060
Immediate Release (IR) in over 1200 patients. The Company's first Phase III
study with NBI-34060-IR was previously initiated in 500 patients in late 2001.
With this ann... |
| | | 02/25/02 | Neurocrine Biosciences to Present at Lehman Brothers 5th Annual Global Healthcare Conference| SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will be presenting at Lehman
Brothers 5th Annual Global Healthcare Conference being held in Orlando,
Florida on Tuesday, February 26, 2002 at 7:15AM Pacific Time (10:15AM Eastern
Time). To hear the live presentation, please dial 1-800-553-3587 (US) or
1-303-713-7920 (International) and reference Neurocrine's ID #1560904. Gary Lyons, President and CEO of Neurocrine ... |
| | | 02/05/02 | Neurocrine Biosciences Reports Financial Results For Fourth Quarter and Year-End 2001| SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial
results for the three and twelve months ended December 31, 2001. The Company
reported a net loss of $14.6 million, or $0.53 per share for the fourth
quarter 2001 as compared to a net loss of $6.5 million, or $0.29 per share for
the same period last year. For the year ending December 31, 2001, the Company
reported a loss of $36.9 million, or $1.42 per share as compared to ... |
| | | 01/29/02 | Neurocrine Biosciences Announces Webcast to Present Year-End Financial Results and Company Update| SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report year-end 2001
financial results on Tuesday, February 5, 2002. Neurocrine will also be
hosting a Webcast to discuss its financial results and provide a company
update on Tuesday, February 5, 2002 at 10:30 AM Eastern Standard Time (EST)/
7:30 AM Pacific Standard Time (PST). Participants may access the Webcast
through a link provided by PRNewswire at
http://... |
| | | 01/18/02 | Neurocrine Biosciences Announces Positive Phase II Efficacy and Safety Results With NBI-34060 Modified Release (MR)| SAN DIEGO, Jan. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive efficacy results with NBI-34060
Modified Release (MR) tablets in a Phase II study in 47 adult patients with
primary (chronic) insomnia with sleep maintenance complaints. This study was a
randomized, multi-center, double-blind, placebo-controlled, five-way
crossover, dose-response study, in which four doses (20 mg, 30 mg, 35 mg, and
40 mg) of MR tablets were tested. The primary ... |
| | | 01/17/02 | Neurocrine Biosciences Announces Webcast to Present Phase II Results With NBI-34060 Modified Release (MR) in Primary (Chronic) Insomnia Patients| SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will be hosting a Webcast
tomorrow on its Phase II efficacy and safety results with NBI-34060 Modified
Release (MR) in patients with primary (chronic) insomnia. The Webcast will be
held Friday, January 18, 2002 at 11:00 AM Eastern Standard Time (EST)/ 8:00 AM
Pacific Standard Time (PST). Participants may access the Webcast through a
link provided by PR Newswire at htt... |
| | | 01/11/02 | Neurocrine Biosciences Amends Shareholder Rights Plan| SAN DIEGO, Jan. 11 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced that its Board of Directors has approved an
amendment of its shareholder rights plan to increase the initial exercise
price of the rights issued pursuant to the plan from $51.75 to $350.00 per
right. The intent of the increase is to preserve the effectiveness of the plan in
view of the recent appreciation of the company's stock price. No other
amendments were made to the plan. Th... |
| | | 01/09/02 | Neurocrine Biosciences to Present at the JPMorgan H&Q 20th Annual Healthcare Conference| SAN DIEGO, Jan. 9 /PRNewswire/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will be presenting at the
JPMorgan H&Q 20th Annual Healthcare Conference being held in San Francisco on
Thursday, January 10, 2002 at 12:00PM Pacific Time (3:00PM Eastern Time). The
presentation will be simultaneously Webcast and can be viewed through a link
provided via the JPMorgan H&Q website at
http://php4.eventsdigital.com/events/jpmhq/healthcare2002 Gary Lyons,... |
| | | 01/03/02 | Neurocrine Biosciences and Taisho Pharmaceutical Initiate A Pivotal Phase IIb Clinical Trial for NBI-6024, A Therapeutic Vaccine for the Treatment of Type I Diabetes| SAN DIEGO, Jan. 3 /PRNewswire/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) and Taisho Pharmaceutical Co., Ltd. today announced that they
have initiated the first pivotal Phase IIb clinical trial of NBI-6024, a
therapeutic vaccine, in approximately 400 adult and adolescent patients with
new onset Type I diabetes. The initiation of this trial with NBI-6024 is the
first of two studies planned. A second Phase IIb trial is planned to begin
during 2002. Successful completion of these two P... |
| |
|
